Business Context and Reporting Period
This Form 8-K filing by Actinium Pharmaceuticals, Inc. (ATNM) reports on corporate governance changes occurring on February 11, 2026, and February 13, 2026. The company is incorporated in Delaware and trades on the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Steve O'Loughlin tendered his resignation as Chief Financial Officer, effective February 27, 2026, to pursue other opportunities. The filing states there were no disagreements with the Company contributing to this resignation.
- Appointment of Principal Financial Officer: On February 13, 2026, the Board appointed Sandesh Seth, the current Chairman and CEO, to serve as the principal financial officer effective February 27, 2026.
Management Commentary and Background
Sandesh Seth has served as CEO since June 2017 and as a Director since March 2012. He brings over 25 years of experience in investment banking, equity research, and the pharmaceutical industry, including roles at Pfizer, Warner-Lambert, and SmithKline. He holds an MBA in Finance from NYU and an M.S. in Pharmaceutical Sciences. The filing notes no family relationships or undisclosed transactions involving Mr. Seth.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (February 27, 2026).
- Verify the interim financial reporting structure while the CEO assumes the CFO role.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics not included in this 8-K.